Company: IOBT
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0000950170-25-070956
Chunk: 3

Company: IO Biotech, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 1A
Chunk 3
---
 to generate revenue and achieve profitability could be impacted if we fail to develop additional product candidates.

·	We rely on third-party suppliers and contract manufacturing organizations (collectively, “CMOs”) to manufacture our product candidates, which can be complex. Our CMOs may encounter difficulties in production, particularly with respect to process development or scale-up of our product candidates. If our CMOs encounter difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped.

·	We will need to obtain substantial additional funding to complete the development and commercialization of our product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.

·	We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than we do.

·	If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.

·	Public health emergencies, geopolitical conflicts or other significant domestic and international events could have a material adverse impact on our business, financial condition and results of operations, including the execution of our clinical trials.